LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Elenco Azioni・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

4.21 1.94

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.05

Massimo

4.21

Metriche Chiave
By Trading Economics
Entrata	21M 61M
Vendite	-74M 48M
P/E Media del settore	28.688 49.8
Margine di Profitto	128.703
Dipendenti	100
EBITDA	-68M 8.8M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+77.73% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	146M 756M
Apertura precedente	2.27
Chiusura precedente	4.21

Notizie sul Sentiment di mercato

By Acuity

80%

20%

325 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

N/A / 0.9337 Supporto e resistenza

Ironwood Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 mag 2026, 23:47 UTC

Discorsi di Mercato

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 mag 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 mag 2026, 23:38 UTC

Discorsi di Mercato

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 mag 2026, 23:14 UTC

Discorsi di Mercato

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 mag 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 mag 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 mag 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 mag 2026, 10:21 UTC

Utili

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 mag 2026, 06:05 UTC

Utili

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 mag 2026, 23:55 UTC

Utili

Review & Preview: Still Going Strong -- Barrons.com

8 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 20:49 UTC

Utili

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mag 2026, 20:25 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Net $115M

8 mag 2026, 19:20 UTC

Discorsi di Mercato

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mag 2026, 19:18 UTC

Utili

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mag 2026, 19:16 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:08 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:05 UTC

Utili

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mag 2026, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mag 2026, 18:51 UTC

Utili

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mag 2026, 18:49 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 18:41 UTC

Utili

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mag 2026, 17:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mag 2026, 17:14 UTC

Utili

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mag 2026, 17:04 UTC

Discorsi di Mercato

Zcash Caps Off Parabolic Week -- Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Ironwood Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

77.73% in crescita

Previsioni per 12 mesi

Media 7.5 USD 77.73%

Alto 10 USD

Basso 5 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ironwood Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 3 che hanno fornito valutazioni azionarie a Ironwood Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 0.9337Supporto e resistenza

Recent bearish events outweigh bullish events.

There are no events.

All events are bearish.

Sentiment

By Acuity

325 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.